Phase II study of cetuximab [Erbitux] for the refractory or relapsed multiple myeloma EMMA-1 (Erbitux for Multiple Myeloma).

Trial Profile

Phase II study of cetuximab [Erbitux] for the refractory or relapsed multiple myeloma EMMA-1 (Erbitux for Multiple Myeloma).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Cetuximab; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms EMMA-1
  • Most Recent Events

    • 12 Jul 2012 Actual end date changed from 30 Nov 2009 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 30 Nov 2009 Actual end date (30 Nov 2009) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top